Stage III NSCLC: low baseline MPV predicts poorer OS

  • Sakin A & al.
  • Sci Rep
  • 8 mar. 2019

  • de Kelli Whitlock Burton
  • Univadis Clinical Summaries
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • Lower pretreatment mean platelet volume (MPV) was an independent risk factor for poor survival in patients with inoperable stage III NSCLC who received concomitant chemoradiotherapy (CCRT).

Why this matters

  • Although other studies have shown an association between low MPV and OS, this is the first in patients with locally advanced NSCLC.
  • MPV is part of a routine blood panel and could be an easy way to identify the best candidates for CCRT.

Study design

  • 115 patients with inoperable stage III NSCLC received CCRT with cisplatin plus etoposide.
  • Funding: None disclosed.

Key results

  • 65 patients had low pretreatment MPV (≤9 fL), and 50 had higher levels (>9 fL).
  • Patients with MPV ≤9 fL had a significantly higher mean total platelet count (TPC; P=.005) and platelet distribution width (P=.027).
  • Overall, median OS was significantly longer in patients with MPV >9.0 fL vs those with MPV ≤9.0 fL (45 vs 19 months; P<.001>
  • OS was better with higher MPV regardless of stage or tumor histology.
  • After multivariable analysis, independent factors of OS were MPV (HR, 0.807; P=.034), Eastern Cooperative Oncology Group Performance Status score (HR, 4.428; P<.001 and total platelet count p=".041).</li">

Limitations

  • Single-center, retrospective study.